Article Text

Extended report
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
  1. Gerd R Burmester1,
  2. William F Rigby2,
  3. Ronald F van Vollenhoven3,
  4. Jonathan Kay4,
  5. Andrea Rubbert-Roth5,
  6. Ariella Kelman6,
  7. Sophie Dimonaco7,
  8. Nina Mitchell7
  1. 1Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
  2. 2Department of Medicine-Rheumatology, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA
  3. 3Department of Medicine, Karolinska Institute, Stockholm, Sweden
  4. 4Rheumatology Center, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA
  5. 5Department of Internal Medicine I, University of Cologne, Cologne, Germany
  6. 6Genentech, South San Francisco, California, USA
  7. 7Roche Products Ltd., Welwyn Garden City, UK
  1. Correspondence to Dr Gerd R Burmester, Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Charitéplatz 1, Berlin 10117, Germany; gerd.burmester{at}charite.de

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.